Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01364181 | The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients | PHASE3 | COMPLETED | 23 | — | — | Mar 1, 2010 | May 1, 2011 | Jun 20, 2011 | 1 | South Korea |
| Arm | Type | Description |
|---|---|---|
| Udenafil | EXPERIMENTAL | Udenafil 50mg qd po |
| Name | Type | Description |
|---|---|---|
| Udenafil | DRUG | Udenafil 50mg qd po |
Inclusion Criteria: * Severe COPD who showed post-bronchodilator forced expiratory volume in 1 second (FEV1) less than 50% of predicted value Exclusion Criteria: * Acute exacerbation within 4 weeks of the study entry * Coronary heart disease * History of adverse event on PDE-5 inhibitors